Mangold Insight initiate coverage of the biotechnology company Biosergen with a buy recommendation and a price target of SEK 2.70 per share. This gives an upside of over 110 percent. The company develops a potent drug against invasive fungal diseases. There is a need for better treatment options against invasive fungal diseases, which have recently received increasing attention in the media and from health organisations, as well as drug companies requiring new candidates. The treatment options that are available have far too many side effects and are developing resistance.
LÄS MER
